184 related articles for article (PubMed ID: 1581831)
1. Immunotherapy of minimal residual disease by immunocompetent lymphocytes and their activation by cytokines.
Slavin S; Ackerstein A; Weiss L; Nagler A; Or R; Naparstek E
Cancer Invest; 1992; 10(3):221-7. PubMed ID: 1581831
[TBL] [Abstract][Full Text] [Related]
2. Use of recombinant human interleukin-2 in conjunction with bone marrow transplantation as a model for control of minimal residual disease in malignant hematological disorders: I. Treatment of murine leukemia in conjunction with allogeneic bone marrow transplantation and IL-2-activated cell-mediated immunotherapy.
Weiss L; Reich S; Slavin S
Cancer Invest; 1992; 10(1):19-26. PubMed ID: 1735011
[TBL] [Abstract][Full Text] [Related]
3. IL-2 activated cell-mediated immunotherapy: control of minimal residual disease in malignant disorders by allogeneic lymphocytes and IL-2.
Slavin S; Ackerstein A; Kedar E; Weiss L
Bone Marrow Transplant; 1990 Jul; 6 Suppl 1():86-90. PubMed ID: 2390644
[TBL] [Abstract][Full Text] [Related]
4. Allogeneic cell therapy in murine B-cell leukemia (BCL1): 1. Alloimmune-mediated graft-versus-leukemia (GVL) effects induced by unmodified and in vitro rIL-2-activated bone marrow and lymphocytes from different lymphoid compartments.
Weiss L; Reich S; Slavin S
Cytokines Cell Mol Ther; 1999 Sep; 5(3):145-52. PubMed ID: 10641572
[TBL] [Abstract][Full Text] [Related]
5. Use of recombinant human interleukin-2 in conjunction with syngeneic bone marrow transplantation in mice as a model for control of minimal residual disease in malignant hematologic disorders.
Ackerstein A; Kedar E; Slavin S
Blood; 1991 Sep; 78(5):1212-5. PubMed ID: 1878588
[TBL] [Abstract][Full Text] [Related]
6. Allogeneic cell-mediated immunotherapy for eradication of minimal residual disease: comparison of T-cell and IL-2 activated killer (LAK) cell-mediated adoptive immunotherapy in murine models.
Vourka-Karussis U; Ackerstein A; Pugatsch T; Slavin S
Exp Hematol; 1999 Mar; 27(3):461-9. PubMed ID: 10089908
[TBL] [Abstract][Full Text] [Related]
7. Effective graft-versus-leukemia effects independent of graft-versus-host disease after T cell-depleted allogeneic bone marrow transplantation in a murine model of B cell leukemia/lymphoma. Role of cell therapy and recombinant IL-2.
Weiss L; Lubin I; Factorowich I; Lapidot Z; Reich S; Reisner Y; Slavin S
J Immunol; 1994 Sep; 153(6):2562-7. PubMed ID: 8077666
[TBL] [Abstract][Full Text] [Related]
8. Allogeneic cell therapy in murine B-cell leukemia (BCL1): 2. The role of non-activated and rIL-2-activated CD4+ and CD8+ T cells in immunotherapy for leukemia.
Weiss L; Reich S; Slavin S
Cytokines Cell Mol Ther; 1999 Sep; 5(3):153-8. PubMed ID: 10641573
[TBL] [Abstract][Full Text] [Related]
9. Induction of graft versus leukemia effects by cell-mediated lymphokine-activated immunotherapy after syngeneic bone marrow transplantation in murine B cell leukemia.
Weiss L; Nusair S; Reich S; Sidi H; Slavin S
Cancer Immunol Immunother; 1996 Oct; 43(2):103-8. PubMed ID: 8954144
[TBL] [Abstract][Full Text] [Related]
10. Spontaneous and IL-2-induced anti-leukemic and anti-host effects against tumor- and host-specific alloantigens.
Cohen P; Vourka-Karussis U; Weiss L; Slavin S
J Immunol; 1993 Nov; 151(9):4803-10. PubMed ID: 8409438
[TBL] [Abstract][Full Text] [Related]
11. The role of purified CD8+ T cells in graft-versus-leukemia activity and engraftment after allogeneic bone marrow transplantation.
Palathumpat V; Dejbakhsh-Jones S; Strober S
Transplantation; 1995 Aug; 60(4):355-61. PubMed ID: 7652765
[TBL] [Abstract][Full Text] [Related]
12. Cytokine-mediated immunotherapy following autologous bone marrow transplantation in lymphoma and evidence of interleukin-2-induced immunomodulation in allogeneic transplants.
Slavin S; Nagler A
Cancer J Sci Am; 1997 Dec; 3 Suppl 1():S59-67. PubMed ID: 9457396
[TBL] [Abstract][Full Text] [Related]
13. Immunotherapy of minimal residual disease in conjunction with autologous and allogeneic bone marrow transplantation (BMT).
Slavin S; Or R; Kapelushnik Y; Drakos P; Ackerstein A; Vourka-Karussis U; Weiss L; Nagler A
Leukemia; 1992 Nov; 6 Suppl 4():164-6. PubMed ID: 1434823
[TBL] [Abstract][Full Text] [Related]
14. Treatment of BCL1 leukemia by transplantation of low density fractions of allogeneic bone marrow and spleen cells.
Palathumpat V; Holm B; Dejbakhsh-Jones S; Strober S
J Immunol; 1992 May; 148(10):3319-26. PubMed ID: 1578152
[TBL] [Abstract][Full Text] [Related]
15. Nonmyeloablative allogeneic bone marrow transplantation as immunotherapy for hematologic malignancies and metastatic solid tumors in preclinical models.
Prigozhina TB; Gurevitch O; Morecki S; Yakovlev E; Elkin G; Slavin S
Exp Hematol; 2002 Jan; 30(1):89-96. PubMed ID: 11823042
[TBL] [Abstract][Full Text] [Related]
16. Induction by interleukin-7 of lymphokine-activated killer activity in lymphocytes from autologous and syngeneic marrow transplant recipients before and after systemic interleukin-2 therapy.
Pavletic Z; Benyunes MC; Thompson JA; Lindgren CG; Massumoto C; Alderson MR; Buckner CD; Fefer A
Exp Hematol; 1993 Sep; 21(10):1371-8. PubMed ID: 8359237
[TBL] [Abstract][Full Text] [Related]
17. Induction of graft-versus-leukemia (GVL) activity in murine leukemia models after IL-2 pretreatment of syngeneic and allogeneic bone marrow grafts.
Zeis M; Uharek L; Glass B; Gaska T; Gassmann W; Mueller-Ruchholtz W
Bone Marrow Transplant; 1994 Nov; 14(5):711-5. PubMed ID: 7889004
[TBL] [Abstract][Full Text] [Related]
18. Correlation between enhancement of graft-versus-leukemia effects following allogeneic bone marrow transplantation by rIL-2 and increased frequency of cytotoxic T-lymphocyte precursors in murine myeloid leukemia.
Leshem B; Vourka-Karussis U; Slavin S
Cytokines Cell Mol Ther; 2000 Sep; 6(3):141-7. PubMed ID: 11140883
[TBL] [Abstract][Full Text] [Related]
19. Suppression and elimination of BCL1 leukemia by allogeneic bone marrow transplantation.
Weiss L; Morecki S; Vitetta ES; Slavin S
J Immunol; 1983 May; 130(5):2452-5. PubMed ID: 6339628
[TBL] [Abstract][Full Text] [Related]
20. Prevention and treatment of relapse by bone marrow transplantation.
Slavin S; Weiss L; Ackerstein A; Vourka-Karussis U; Morecki S; Or R; Nagler A; Kapelushnik J; Delukina M; Drakos P
Bone Marrow Transplant; 1993; 12 Suppl 3():S54-6. PubMed ID: 8124259
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]